Carter to lead Fusion Energy Division at Oak Ridge National Laboratory
Pengfei Cao, a polymer chemist at ORNL, has been chosen to receive a 2021 Young Investigator Award from the Polymeric Materials: Science and Engineering Division of the American Chemical Society, or ACS PMSE.
As the United States transitions to clean energy, the country has an ambitious goal: cut carbon dioxide emissions in half by the year 2030, if not before. One of the solutions to help meet this challenge is found at ORNL as part of the Better Plants Program.
Researchers at ORNL have developed a robotic disassembly system for spent electric vehicle battery packs to safely and efficiently recycle and reuse critical materials while reducing toxic waste.
Four first-of-a-kind 3D-printed fuel assembly brackets, produced at the Department of Energy’s Manufacturing Demonstration Facility at Oak Ridge National Laboratory, have been installed and are now under routine operating
Joseph Pickel has been elected a 2021 fellow of the American Chemical Society, or ACS. Pickel supports the Fusion and Fission Energy and Sciences Directorate as environment, safety and health
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Six science and technology innovators from across the United States will join the fifth cohort of Oak Ridge National Laboratory’s Innovation Crossroads program in June.
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
When COVID-19 was declared a pandemic in March 2020, Oak Ridge National Laboratory’s Parans Paranthaman suddenly found himself working from home like millions of others.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.